Literature DB >> 28840619

Adding C-reactive protein and procalcitonin to the model of end-stage liver disease score improves mortality prediction in patients with complications of cirrhosis.

Sakkarin Chirapongsathorn1, Worawan Bunraksa1, Amnart Chaiprasert2, Dollapas Punpanich3, Ouppatham Supasyndh2, Patrick S Kamath4.   

Abstract

BACKGROUND AND AIM: This study aims to determine the performance of models adding C-reactive protein (CRP) and procalcitonin (PCT) to the model of end-stage liver disease (MELD) score for mortality prediction in patients hospitalized with complications of cirrhosis.
METHODS: A prospective cohort study was carried out in consecutive cirrhotic patients admitted with complications of cirrhosis between September 2012 and December 2013 at Phramongkutklao Hospital, Bangkok, Thailand. All patients had venous CRP, PCT, and laboratory values for MELD score calculation measured at emergency room or admission. Cox regression analysis and the c-statistic were used to predict mortality. The MELD-CRP score was externally validated in 818 eligible patients from Mayo Clinic, Rochester, using data from 1288 cirrhotic patients diagnosed between 2010 and 2014.
RESULTS: A cohort of 177 patients with cirrhosis was admitted during the study period. Seventy-one patients were eligible for analysis. The MELD score was predictive of 90-day mortality odds ratio (OR) 1.19 (95% confidence interval [CI] 1.09-1.32). Adding CRP and/or PCT to the MELD score improved the predictive of 90-day mortality: MELD-CRP OR 2.71 (95% CI 1.66-4.99); MELD-PCT OR 2.72 (95% CI 1.66-4.99); MELD-CRP-PCT OR 2.71 (95% CI 1.67-4.92). The c-statistics for MELD, MELD-CRP, MELD-PCT, and MELD-CRP-PCT were 0.81, 0.83, 0.84, and 0.85, respectively. Adding CRP and/or PCT to the MELD score also improved 30-day mortality prediction. Similar results for the MELD-CRP score were obtained from the Mayo Clinic external validation cohort.
CONCLUSION: The MELD-CRP, MELD-PCT, and MELD-CRP-PCT scores may be superior to the MELD score alone in predicting mortality in patients hospitalized with complications of cirrhosis.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  C-reactive protein (CRP); MELD score; cirrhosis; procalcitonin

Mesh:

Substances:

Year:  2018        PMID: 28840619     DOI: 10.1111/jgh.13928

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

1.  CRP and the Prognosis of Patients with Cirrhosis.

Authors:  Nicoleta State
Journal:  Maedica (Bucur)       Date:  2021-09

2.  C-reactive protein concentration as a risk predictor of mortality in intensive care unit: a multicenter, prospective, observational study.

Authors:  Rong Qu; Linhui Hu; Yun Ling; Yating Hou; Heng Fang; Huidan Zhang; Silin Liang; Zhimei He; Miaoxian Fang; Jiaxin Li; Xu Li; Chunbo Chen
Journal:  BMC Anesthesiol       Date:  2020-11-23       Impact factor: 2.217

Review 3.  Role of Polypeptide Inflammatory Biomarkers in the Diagnosis and Monitoring of COVID-19.

Authors:  Aparajita Sen; Arti Nigam; Meenakshi Vachher
Journal:  Int J Pept Res Ther       Date:  2022-01-24       Impact factor: 2.191

4.  The Diagnostic and Prognostic Values of C-Reactive Protein and Procalcitonin during Bacterial Infections in Decompensated Cirrhosis.

Authors:  Sana Khedher; Nasreddine Fouthaili; Amira Maoui; Sirine Lahiani; Mohamed Salem; Kahena Bouzid
Journal:  Gastroenterol Res Pract       Date:  2018-12-30       Impact factor: 2.260

5.  Thirty-Day Readmission and Cost Analysis in Patients With Cirrhosis: A Nationwide Population-Based Data.

Authors:  Sakkarin Chirapongsathorn; Kittiyod Poovorawan; Ngamphol Soonthornworasiri; Wirichada Pan-Ngum; Kamthorn Phaosawasdi; Sombat Treeprasertsuk
Journal:  Hepatol Commun       Date:  2020-01-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.